open access

Ahead of Print
Research paper
Published online: 2022-02-11
Get Citation

Level of IGF1 in follicular fluid associated with IVF pregnancy outcome in the application of growth hormone

Luo Man1, Yuanyuan Chen1, Nannan Li1, Yan Luo1, Xiangyang Pan1, Shaoming Zhou1
Affiliations
  1. Department of Administration, The Maternal and Child Health Care Hospital of Hunan Province, Changsha, Hunan, China

open access

Ahead of Print
ORIGINAL PAPERS Gynecology
Published online: 2022-02-11

Abstract

Objectives: The combination of growth hormone (GH) with gonadotropin was a prevalent method to improve clinical reproduction in adjuvant for assisted reproduction treatment (ART). However, the contradictory results from previous studies failed to confirm the benefits. The present study is focused on the mechanism analysis of GH-IGF1-gonadal axis in ART and the changes of IGF1 in follicular fluid among different types of patients.

Material and methods: We recruited 136 patients and divided them into eight groups according to their ages and ovarian reserves. The baseline characteristics of the study population were summarized. The therapeutic outcomes in the study population were observed. In the meantime, concentrations of IGF1 in follicular fluids from different types of patients who underwent GH strategy were measured by Western blot. The functional mechanism of GH-IGF1-gonadal axis in ART was also analyzed.

Results: We analyzed the baseline characteristics of the study population, the therapeutic outcome of GH-IGF-1-gonadal axis, as well as the relative protein level of IGF1 and IGFBP1 in follicular fluid from different groups. The chemical pregnancy rate was significantly increased in different degrees for groups with GH co-treatment compared to groups without GH co-treatment. The IGF1 in follicular fluid of patients under 35 years’ old showed an upward trend compared with groups of poor, normal and high ovarian reserves. After GH induction, IGF1 in follicular fluid was significantly increased in patients over 35 years old.

Conclusions: The study suggested that the application of GH might be beneficial to the pregnancy outcome in patients. GH application in patients older than 35 years might have a beneficial effect on pregnancy outcome via promoting the expression of IGF1. Our study indicates a different mechanism from GH application among younger and older patient in ART and provides a new clue for individual clinical treatment in infernity patients.

Abstract

Objectives: The combination of growth hormone (GH) with gonadotropin was a prevalent method to improve clinical reproduction in adjuvant for assisted reproduction treatment (ART). However, the contradictory results from previous studies failed to confirm the benefits. The present study is focused on the mechanism analysis of GH-IGF1-gonadal axis in ART and the changes of IGF1 in follicular fluid among different types of patients.

Material and methods: We recruited 136 patients and divided them into eight groups according to their ages and ovarian reserves. The baseline characteristics of the study population were summarized. The therapeutic outcomes in the study population were observed. In the meantime, concentrations of IGF1 in follicular fluids from different types of patients who underwent GH strategy were measured by Western blot. The functional mechanism of GH-IGF1-gonadal axis in ART was also analyzed.

Results: We analyzed the baseline characteristics of the study population, the therapeutic outcome of GH-IGF-1-gonadal axis, as well as the relative protein level of IGF1 and IGFBP1 in follicular fluid from different groups. The chemical pregnancy rate was significantly increased in different degrees for groups with GH co-treatment compared to groups without GH co-treatment. The IGF1 in follicular fluid of patients under 35 years’ old showed an upward trend compared with groups of poor, normal and high ovarian reserves. After GH induction, IGF1 in follicular fluid was significantly increased in patients over 35 years old.

Conclusions: The study suggested that the application of GH might be beneficial to the pregnancy outcome in patients. GH application in patients older than 35 years might have a beneficial effect on pregnancy outcome via promoting the expression of IGF1. Our study indicates a different mechanism from GH application among younger and older patient in ART and provides a new clue for individual clinical treatment in infernity patients.

Get Citation

Keywords

growth hormone, IGF-1, follicular fluid, in vitro fertilization

Supp./Additional Files (1)
Title Page
Download
27KB
About this article
Title

Level of IGF1 in follicular fluid associated with IVF pregnancy outcome in the application of growth hormone

Journal

Ginekologia Polska

Issue

Ahead of Print

Article type

Research paper

Published online

2022-02-11

Page views

781

Article views/downloads

531

DOI

10.5603/GP.a2021.0232

Pubmed

35156695

Keywords

growth hormone
IGF-1
follicular fluid
in vitro fertilization

Authors

Luo Man
Yuanyuan Chen
Nannan Li
Yan Luo
Xiangyang Pan
Shaoming Zhou

References (18)
  1. Fortin CS, Leader A, Mahutte N, et al. Gene expression analysis of follicular cells revealed inflammation as a potential IVF failure cause. J Assist Reprod Genet. 2019; 36(6): 1195–1210.
  2. García D, Brazal S, Rodríguez A, et al. Knowledge of age-related fertility decline in women: A systematic review. Eur J Obstet Gynecol Reprod Biol. 2018; 230: 109–118.
  3. Nørgård BM, Larsen MD, Friedman S, et al. Decreased chance of a live born child in women with rheumatoid arthritis after assisted reproduction treatment: a nationwide cohort study. Ann Rheum Dis. 2019; 78(3): 328–334.
  4. Aguiar-Oliveira MH, Bartke A. Growth Hormone Deficiency: Health and Longevity. Endocr Rev. 2019; 40(2): 575–601.
  5. Correa FA, Bianchi PHM, Franca MM, et al. Successful pregnancies after adequate hormonal replacement in patients with combined pituitary hormone deficiencies. J Endocr Soc. 2017; 1(10): 1322–1330.
  6. INVALID CITATION ! [12-14.
  7. Norman RJ, Alvino H, Hull LM, et al. LIGHT investigators. Human growth hormone for poor responders: a randomized placebo-controlled trial provides no evidence for improved live birth rate. Reprod Biomed Online. 2019; 38(6): 908–915.
  8. Dosouto C, Calaf J, Polo A, et al. Growth Hormone and Reproduction: Lessons Learned From Animal Models and Clinical Trials. Frontiers in Endocrinology. 2019; 10.
  9. Carter-Su C, Schwartz J, Argetsinger LS. Growth hormone signaling pathways. Growth Horm IGF Res. 2016; 28: 11–15.
  10. List EO, Sackmann-Sala L, Berryman DE, et al. Endocrine parameters and phenotypes of the growth hormone receptor gene disrupted (GHR-/-) mouse. Endocr Rev. 2011; 32(3): 356–386.
  11. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310(20): 2191–2194.
  12. Tesarik J, Greco E, Mendoza C. Late, but not early, paternal effect on human embryo development is related to sperm DNA fragmentation. Hum Reprod. 2004; 19(3): 611–615.
  13. Carter-Su C. Growth hormone signal transduction. Growth Hormone & IGF Research. 1998; 8(4): 311.
  14. Wondisford F. Growth Hormone. Essentials of Endocrinology and Metabolism. 2020: 229–240.
  15. Cui N, Li AM, Luo ZY, et al. Effects of growth hormone on pregnancy rates of patients with thin endometrium. J Endocrinol Invest. 2019; 42(1): 27–35.
  16. Hrabia A, Sechman A, Gertler A, et al. Effect of growth hormone on steroid content, proliferation and apoptosis in the chicken ovary during sexual maturation. Cell Tissue Res. 2011; 345(1): 191–202.
  17. Hull KL, Harvey S. Growth hormone and reproduction: a review of endocrine and autocrine/paracrine interactions. Int J Endocrinol. 2014; 2014: 234014.
  18. European Society for Paediatric Endocrinology (ESPE). 2016.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl